Breakthrough in Prostate Cancer Treatment: New Drugs Extend Life Expectancy
Metastatic Prostate Cancer Patients Benefit from PARP Inhibitors
Men with metastatic prostate cancer now have extended lifespans thanks to the remarkable findings of a new study conducted by a team at the Institute of Cancer Research. Their discovery suggests that olaparib, a type of PARP inhibitor, could revolutionize prostate cancer treatment.
Promising New Treatment Options for Prostate Cancer
Separately, investigators at Cedars-Sinai Cancer have also made significant advancements in prostate cancer treatment by identifying two promising new options. The development of a novel immunotherapy using nanoparticles has shown promising results in delaying resistance to hormone therapy.
Comments